REGENERON PHARMACEUTICALS, INC. 8-K

What Happened

• Regeneron Pharmaceuticals, Inc. filed an 8-K on April 8, 2026 (Item 2.02) reporting it currently expects an acquired in‑process research and development (IPR&D) charge of approximately $102 million (pre‑tax) in its first-quarter 2026 results. The company said this charge will reduce both GAAP and non‑GAAP net income per diluted share by about $0.81 for the quarter. Regeneron’s Q1 2026 results are preliminary, unaudited and subject to closing procedures; actual results may differ.

Key Details

• Estimated acquired IPR&D charge: ~ $102 million (pre‑tax) for Q1 2026.
• Expected EPS impact: ~ $0.81 reduction to both GAAP and non‑GAAP diluted EPS for the quarter.
• Charge primarily stems from premiums on equity securities purchased and development milestone and up‑front payments under collaboration and licensing agreements.
• Regeneron does not forecast such acquired IPR&D charges routinely due to uncertainty in timing and magnitude; non‑GAAP measures exclude certain non‑cash/reconciling items and include an estimated tax effect.

Why It Matters

• The one‑time IPR&D charge will lower reported quarterly earnings (both GAAP and the company’s non‑GAAP metric) and can affect investor comparisons to prior quarters and analysts’ EPS expectations. While management excludes these types of items from its non‑GAAP performance measures, they still reduce reported net income for the period. Investors should note results are preliminary and forward‑looking statements in the filing are subject to the risks and uncertainties described by the company.